Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 135

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1A
Chunk 135
---
 business strategy plan includes the identification of additional animal care products we may license, acquire, or develop, and
then commercializing such products into a branded product portfolio along with Spryng®. Even if we successfully license, acquire
or develop such animal care products from our proprietary technology, or acquire any such new products, we may still fail to commercialize
them successfully for various reasons, including competitors offering alternative products which are more effective than ours, our discovery
of third-party IP rights already covering the products, harmful side effects caused to animals by the products, inability to produce
products in commercial quantities at an acceptable cost, or the products not being accepted by veterinarians and pet owners as being
safe or effective. If we fail to successfully obtain and commercialize future new animal care products, our business and prospects may
be harmed substantially.

We
will rely on third parties to conduct studies of our current and new products, and if these third parties do not successfully perform
their contracted commitments effectively or substantially fail to meet expected study deadlines, we could be delayed from effectively
commercializing our future products.

We
have entered into a clinical trial services agreement with Colorado State University and Ethos Veterinary Health. In the future, we may
engage other educational institutions with a veterinary medical curriculum to conduct studies of Spryng® and other products to be
introduced by us. We expect to have limited control over the timing and resources that such third parties will devote to the studies.
Although we must rely on third parties to conduct our studies, we remain responsible for ensuring any of our studies are conducted in
compliance with protocols, regulations, and standards set by industry regulatory authorities and commonly referred to as current good
clinical practices (“cGCPs”) and good laboratory practices (“GLPs”). These required clinical and laboratory practices
include many items regarding the conducting, monitoring, recording, and reporting the results of target animal studies to ensure that
the data and results of these studies are objective and scientifically credible and accurate.

Our
success is highly dependent on the clinical advancement of our products and adverse results in clinical trials and other studies could
prevent us from effectively commercializing our future products

There
can be no assurance that clinical trials or studies of Spryng® and our other products will demonstrate the safety and
efficacy of such products in a statistically significant manner. Failure to show efficacy or adverse results in clinical trials or studies
could significantly harm our business. While some clinical trials and studies of our product candidates may show indications